Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegavivint in Relapsed/Refractory C-MYC Overexpressing Large B-Cell Lymphoma
NCT05755087Phase 1Recruiting
- Start
- Mar 2023
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegavivint in diffuse large B-cell lymphoma (DLBCL). Primary endpoints: Incidence of dose-limiting toxicity at 4 weeks, Maximum tolerated dose at 4 weeks and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
tegavivint
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05755087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755087.